Vilatobá M, Eckhoff DE, Contreras JL

Idioma: Español
Referencias bibliográficas: 40
Paginas: 244-251
Archivo PDF: 135.43 Kb.

RESUMEN

En los últimos años han existido avances importantes en el trasplante hepático. La evolución en la cirugía hepática y la aparición de mejores inmunosupresores han incrementado de manera importante el éxito en el trasplante hepático. Este éxito ha aumentado el número de receptores; sin embargo, al mismo tiempo el número de órganos ha permanecido estable en los últimos 10 años, teniendo como resultado un incremento en la disparidad entre donadores y receptores. Por lo tanto es necesario conocer quiénes son los mejores candidatos para un trasplante hepático. En este artículo se revisarán las indicaciones y contraindicaciones en el trasplante hepático en la era de la clasificación de MELD (por sus siglas en inglés Model for End Stage Liver Disease).

REFERENCIAS (EN ESTE ARTÍCULO)

1. Starzl TE. History of clinical transplantation. World J Surg 2000; 24: 759-82.

2. Gines P, Arroyo V, Rodes J. Pathophysiology, complications, and treatment of ascites. Clin Liver Dis 1997; 1: 129-55.

3. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003; 362: 1819-27.

4. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363: 1461-8.

5. Lima BL, Franca AV, Pazin-Filho A, Araujo WM, Martinez JA, Maciel BC, Simoes MV, Terra-Filho J, Martinelli AL. Frequency, clinical characteristics, and respiratory parameters of hepatopulmonary syndrome. Mayo Clin Proc 2004; 79: 42-8.

6. O’Brien JD, Ettinger NA. Pulmonary complications of liver transplantation. Clin Chest Med 1996; 17: 99-114.

7. Saab S, Han SH, Martin P. Liver transplantation. Selection, listing criteria, and preoperative management. Clin Liver Dis 2000; 4: 513-32.

8. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keefe EB, Kneteman NM, Lake JR, Martin P, Rakela J, Shiffman ML, So S, Wiesner RH. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Dis-eases. Transpl 1998; 66: 956-62.

9. Freeman RB Jr., Edwards EB. Liver transplant waiting time does not correlate with waiting list mortality: implications for liver allocation policy. Liver Transpl 2000; 6: 543-52.

10. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatol 2001; 33: 464-70.

11. Freeman RB, Rohrer RJ, Katz E, Lewis WD, Jenkins R, Cosimi AB, Delmonico F, Friedman A, Lorber M, O’Connor K, Brad-ley J. Preliminary results of a liver allocation plan using a continuous medical severity score that de-emphasizes waiting time. Liver Transpl 2001; 7: 173-8.

12. Merion RM. When a patient is too well and when is a patient too sick for a liver transplant? Liver Transpl 2004; 10: S69-S73.

13. Gonwa TA. Treatment of renal dysfunction after orthotopic liver transplantation: options and outcomes. Liver Transpl 2003; 9: 778-9.

14. Pikul J, Sharpe MD, Lowndes R, Ghent CN. Degree of preoperative malnutrition is predictive of postoperative morbidity and mortality in liver transplant recipients. Transpl 1994; 57: 469-72.

15. Cabre E, Gassull MA. Nutritional aspects of liver disease and transplantation. Curr Opin Clin Nutr Metab Care 2001; 4: 581-9.

16. MacQuillan GC, Neuberger J. Liver transplantation for primary biliary cirrhosis. Clin Liver Dis 2003; 7: 941-56, ix.

17. Farges O, Malassagne B, Sebagh M, Bismuth H. Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surg 1995; 117: 146-55.

18. Solano E, Khakhar A, Bloch M, Quan D, McAlister V, Ghent C, Wall W, Marotta P. Liver transplantation for primary sclerosing cholangitis. Transplant Proc 2003; 35: 2431-4.

19. Sanchez-Urdazpal L, Czaja AJ, van HB, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatol 1992; 15: 215-21.

20. Howard LM, Williams R, Fahy TA. The psychiatric assessment of liver transplant patients with alcoholic liver disease: a review. J Psychosom Res 1994; 38: 643-53.

21. Prince MI, Hudson M. Liver transplantation for chronic liver disease: advances and controversies in an era of organ shortag-es. Postgrad Med J 2002; 78: 135-41.

22. Neuberger J, Schulz KH, Day C, Fleig W, Berlakovich GA, Berenguer M, Pageaux GP, Lucey M, Horsmans Y, Burroughs A, Hockerstedt K. Transplantation for alcoholic liver disease. J Hepatol 2002; 36: 130-7.

23. Ben-Ari Z, Mor E, Tur-Kaspa R. Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature. J Intern Med 2003; 253: 544-52.

24. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss JA, Schmidt P, Pakrasi A, Artinian L, Mur-ray NG, Imagawa DK, Holt C, Goldstein LI, Stribling R, Busuttil RW. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatol 1998; 28: 585-9.

25. Curry MP. Hepatitis B and hepatitis C viruses in liver transplantation. Transpl 2004; 78: 955-63.

26. Neuberger J. Developments in liver transplantation. Gut 2004; 53: 759-68.

27. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-S9.

28. Davis GL. Chronic hepatitis C and liver transplantation. Rev Gastroenterol Disord 2004; 4: 7-17.

29. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transpl 2004; 77: 226-31.

30. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-5.

31. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, Van Der WW, Lauwers G, Liu C, Crawford JM, Davis GL, Nelson DR. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recur-rent hepatitis C. Liver Transpl 2002; 8: 1000-6.

32. Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003; 9: S90-S94.

33. Davis GL. Treatment of acute and chronic hepatitis C. Clin Liv-er Dis 1997; 1: 615-30.

34. Marsh JW, Geller DA, Finkelstein SD, Donaldson JB, Dvorchik I. Role of liver transplantation for hepatobiliary malignant dis-orders. Lancet Oncol 2004; 5: 480-8.

35. Helton WS, Di BA, Chari R, Schwartz M, Bruix J. Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2003; 7: 401-11.

36. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10: S115-S120.

37. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.

38. Farmer DG, Anselmo DM, Ghobrial RM, Yersiz H, McDiarmid SV, Cao C, Weaver M, Figueroa J, Khan K, Vargas J, Saab S, Han S, Durazo F, Goldstein L, Holt C, Busuttil RW. Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. Ann Surg 2003; 237: 666-75.

39. Bailey B, Amre DK, Gaudreault P. Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med 2003; 31: 299-305.

40. O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterol 1989; 97: 439-45.